 In this study, researchers examined the role of a specific circular INA, CERC 0030018, in glioma tumorigenesis and progression. They found that CERC 0030018 was significantly downregulated when glioma cells were treated with isolequotygenin, ISL, which is known to have antioxidant and anti-tumor properties. The researchers also discovered that CERC 0030018 silencing reduced glioma cell growth and invasion, as well as increased cellular oxidative stress. Further investigation revealed that CERC 0030018 may be involved in the regulation of her 2-MIR-1236 signaling, which plays a key role in glioma development and progression. Taken together, these results suggest that CERC 0030018 may serve as a biological signature or therapeutic target for glioma. This article was authored by Aikun Liu, Baohong Jiang, Kailu Song and others. We are article.tv, links in the description below.